History of Development, Classification, Mechanism of Action and Rational Application of Major Anti-Hypertensive Drugs
DOI:
https://doi.org/10.62051/ijphmr.v1n2.07Keywords:
Angioplasty-converting enzyme inhibitors, Calcium channel blockers, Adrenergic receptor antagonists, Diuretics, Central anti-hypertensive and vasodilation agentsAbstract
With the rise of the aging population, the number of people with high blood pressure is increasing. Hypertension can cause cerebral hemorrhage, cerebral infarction, heart failure, coronary atherosclerotic heart disease and renal failure. One of the most common treatments for hypertension is drug therapy. Common anti-hypertensive drugs include angioplasty-converting enzyme inhibitors, calcium channel blockers, adrenergic receptor antagonists, diuretics, central anti-hypertensive drugs and vasodilation. The types of drugs used vary depending on the individual's condition. This article reviews the development history, classification, mechanism of action and rational application of the major anti-hypertensive drugs, so that more people can understand hypertension and provide more choices of drugs for hypertensive people.
References
Roth, G.A., Mensah, G.A., Johnson, C.O, et al. (2021) Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study. J Am Coll, 77(15):1958-1959.
Ma, L., Wang, Z., Fan, J., et al. (2022) China Cardiovascular Health and Disease Report 2021 on the current status of hypertension prevalence and prevention in China. Chinese Family Medicine, 25(30):3715-3720.
Chen, Z., Du, J. (2022) Pharmacology 9th edition. People's Health Publishing House, Beijing.
Chen, F., Hu, J. (2010) Progress of research on new anti-hypertensive drugs. Practical Geriatrics, 24(05):416-418.
Gong, P. (2006) Evaluation and research progress of antihypertensive drugs. Chinese Society of Pharmacology, National Pharmaceutical Academic Exchange Conference and Training Course on Progress in Clinical Pharmacology Research, 55-59.
Linz, W., Wiemer, G., Gohlke, P., et al. (1995) Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev, 47 (1):25-49.
You, Q. (2016) Medicinal chemistry 8th edition. People's Health Press, Beijing.
Zhu, L., Zhou, J. (2013) Mechanism of action of inhibitors of renin-angiotensin-aldosterone system. Shanghai Medicine, 34(17):3-5.
Shen, Y., Zhang, G., Wang, J. (2019) Evaluation of the effect of chlorosartan potassium tablets in the treatment of essential hypertension. Shenzhen Journal of Integrated Chinese and Western Medicine, 29(16):160-161.
Luo, S., Zhou, X., Xie, D. (2015) Effect of aliskiren on metabolic remodeling in heart failure. Chongqing Medicine, 44(21):2887-2889.
Li Sujuan, Guo Jianqiang. Progress of renin inhibitor aliskiren in the treatment of hypertension. Medical Review, 2015, 21(7):1250-1252.
Wang, X., Zhang, Y., Tan, X., et al. (2023) Progress of antihypertensive and nephroprotective effects of aliskiren. Shandong Chemical Industry, 52(06):71-73.
Liu, H. (2020) Research progress of beta-blockers combined with calcium channel antagonists in the treatment of hypertension. Modern Diagnosis and Treatment, 31(02):196-199.
Li, H., Peng, W., Wu, S. (2023) β-blockers in hypertension in young and middle-aged people. Chinese general medicine, 26(02).
Wang, D. (2019) Study on the clinical progress of diuretics combined with other drugs against hypertension. Famous Doctor, 72(05):262.
Kong, Y., Gao, P. (2011) Revisiting the position of diuretics in the treatment of hypertension. Journal of Clinical Internal Medicine, 28(1):13-15.
Guo, W. (2019) Thiazide diuretics in the treatment of hypertensive patients. Medical Equipment, 32(02):142-143.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
